Hemostemix (CVE:HEM) Shares Up 27.8% – Time to Buy?

Hemostemix Inc. (CVE:HEMGet Free Report) shares were up 27.8% during mid-day trading on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 335,071 shares changed hands during trading, a decline of 31% from the average daily volume of 486,759 shares. The stock had previously closed at C$0.09.

Hemostemix Stock Up 27.8%

The business’s fifty day moving average price is C$0.10 and its 200 day moving average price is C$0.14. The firm has a market capitalization of C$16.76 million, a price-to-earnings ratio of -3.35 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.

Insider Transactions at Hemostemix

In related news, Director Peter Alan Lacey purchased 200,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average price of C$0.15 per share, for a total transaction of C$30,000.00. Insiders own 10.43% of the company’s stock.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

See Also

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.